KR20080074202A - 에스트로겐 암 요법 - Google Patents

에스트로겐 암 요법 Download PDF

Info

Publication number
KR20080074202A
KR20080074202A KR1020087015960A KR20087015960A KR20080074202A KR 20080074202 A KR20080074202 A KR 20080074202A KR 1020087015960 A KR1020087015960 A KR 1020087015960A KR 20087015960 A KR20087015960 A KR 20087015960A KR 20080074202 A KR20080074202 A KR 20080074202A
Authority
KR
South Korea
Prior art keywords
estrogen
cancer
patient
paclitaxel
poly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020087015960A
Other languages
English (en)
Korean (ko)
Inventor
잭 싱어
Original Assignee
셀 쎄러퓨틱스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37891993&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20080074202(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 셀 쎄러퓨틱스 인코포레이티드 filed Critical 셀 쎄러퓨틱스 인코포레이티드
Publication of KR20080074202A publication Critical patent/KR20080074202A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020087015960A 2005-12-06 2006-12-05 에스트로겐 암 요법 Withdrawn KR20080074202A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US74272505P 2005-12-06 2005-12-06
US60/742,725 2005-12-06
US81422106P 2006-06-16 2006-06-16
US60/814,221 2006-06-16

Publications (1)

Publication Number Publication Date
KR20080074202A true KR20080074202A (ko) 2008-08-12

Family

ID=37891993

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087015960A Withdrawn KR20080074202A (ko) 2005-12-06 2006-12-05 에스트로겐 암 요법

Country Status (9)

Country Link
US (1) US20070167349A1 (enExample)
EP (1) EP1957065A1 (enExample)
JP (1) JP2009518406A (enExample)
KR (1) KR20080074202A (enExample)
CA (1) CA2630553A1 (enExample)
PE (1) PE20070701A1 (enExample)
RU (1) RU2008127309A (enExample)
TW (1) TWI322010B (enExample)
WO (1) WO2007067498A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010014250A1 (en) * 2008-08-01 2010-02-04 Cell Therapeutics, Inc. Prediction of cancer therapy based on cathespin b levels
WO2010014249A1 (en) * 2008-08-01 2010-02-04 Cell Therapeutics, Inc. Cancer therapy comprising estrogen inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4942184A (en) * 1988-03-07 1990-07-17 The United States Of America As Represented By The Department Of Health And Human Services Water soluble, antineoplastic derivatives of taxol
GB9120653D0 (en) * 1991-09-27 1991-11-06 Procter & Gamble Dispensing agent
US5731316A (en) * 1996-01-30 1998-03-24 The Stehlin Foundation For Cancer Research Derivatives of camptothecin and methods of treating cancer using these derivatives
US6441025B2 (en) * 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
US5977163A (en) * 1996-03-12 1999-11-02 Pg-Txl Company, L. P. Water soluble paclitaxel prodrugs
CA2366697A1 (en) * 1999-02-26 2000-08-31 Larry Helson Treatment regimen for hormone-sensitive cancers
JP2003511423A (ja) * 1999-10-12 2003-03-25 セル・セラピューティックス・インコーポレーテッド ポリグルタメート−治療薬コンジュゲートの製造

Also Published As

Publication number Publication date
TWI322010B (en) 2010-03-21
TW200803836A (en) 2008-01-16
CA2630553A1 (en) 2007-06-14
PE20070701A1 (es) 2007-07-20
WO2007067498A1 (en) 2007-06-14
RU2008127309A (ru) 2010-01-20
JP2009518406A (ja) 2009-05-07
US20070167349A1 (en) 2007-07-19
EP1957065A1 (en) 2008-08-20

Similar Documents

Publication Publication Date Title
US20230372499A1 (en) Dendrimer compositions and methods for drug delivery
EP2433653B1 (en) Use of aprotinin polypeptides as carriers in pharmaceutical conjugates
Kaminskas et al. Methotrexate-conjugated PEGylated dendrimers show differential patterns of deposition and activity in tumor-burdened lymph nodes after intravenous and subcutaneous administration in rats
US20230263729A1 (en) Poly(ethylene glycol)-block-poly(propylene sulfide) nanocarrier platform for enhanced efficacy of immunosuppressive agents
AU2018368520B2 (en) Ligand-drug-conjugates as substrates for selective cleavage by the exopeptidase activity of Cathepsin B
Zou et al. α3β1 integrin-targeting polymersomal docetaxel as an advanced nanotherapeutic for nonsmall cell lung cancer treatment
JP2022513400A (ja) ペプチド含有リンカーを有するシステイン操作抗体－薬物コンジュゲート
Lee et al. Photo-induced crosslinked and anti-PD-L1 peptide incorporated liposomes to promote PD-L1 multivalent binding for effective immune checkpoint blockade therapy
JP2023548310A (ja) Ｆａｐ活性化血清半減期延長型治療用コンジュゲート
KR20220004042A (ko) 나노캡슐로 제형화된 항-kras 항체의 세포내 전달
Cillari et al. Harnessing sulfur-doped carbon nanodots conjugated with IDO inhibitors act as a dual-mode breast cancer immunotherapy
Sun et al. A potential platform of combining sialic acid derivative-modified paclitaxel cationic liposomes with antibody–drug conjugates inspires robust tumor-specific immunological memory in solid tumors
EP4233868A1 (en) Use of folic acid and folic acid-modified b cell lymphoma inducing b cell immune tolerance and targeting migm positive expression
Ma et al. Polyglycerol-Shelled reduction-sensitive polymersome for DM1 delivery to HER-2-Positive breast cancer
KR20080074202A (ko) 에스트로겐 암 요법
WO2019079767A1 (en) IMMUNOTHERAPEUTIC AGENTS TARGETING MACROPHAGES
AU2012237786B2 (en) Method and composition for enhancing target cells uptake of therapeutic agents
MX2008007281A (en) Estrogen cancer therapy
Nguyen Chemical modification of drugs to promote their self-assembly into nanoparticles for improved delivery
WO2025166213A1 (en) Treatment of head and neck cancer with pharmaceutical composition comprising nanoparticles containing taxane
WO2026030286A1 (en) Drug-lipid conjugated layer-by-layer nanoparticle for glioblastoma treatment
HK40081468A (en) Dendrimer compositions and methods for drug delivery
Walker PSMA-1-Doxorubicin Conjugates for Targeted Therapy of Prostate Cancer
WO2010014250A1 (en) Prediction of cancer therapy based on cathespin b levels
Simic Simic, L.

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20080630

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid